Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000899243-18-030742
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-12-12 18:50:31
Reporting Period:
2016-03-24
Accepted Time:
2018-12-12 18:50:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1596946 Quotient Ltd QTNT In Vitro & In Vivo Diagnostic Substances (2835) 264719797
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1604877 Frederick Hallsworth 28 Esplanade
St Helier Y9 JE2 3QA
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2016-03-24 22 $8.59 55,091 No 4 S Direct
Ordinary Shares Disposition 2017-03-23 26 $6.65 55,065 No 4 S Direct
Ordinary Shares Disposition 2018-03-21 28 $6.21 55,037 No 4 S Direct
Ordinary Shares Acquisiton 2018-12-11 10,000 $6.50 65,037 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Ordinary Shares Ordinary Share Option (Right to Buy) $11.62 2025-10-31 7,505 7,505 Direct
Ordinary Shares Ordinary Share Option (Right to Buy) $8.00 2024-04-29 5,000 5,000 Direct
Ordinary Shares Option to Purchase Ordinary Shares $0.00 2014-02-13 2022-08-30 20,014 20,014 Direct
Ordinary Shares Ordinary Share Option (Right to Buy) $9.95 2024-10-31 5,025 5,025 Direct
Ordinary Shares Ordinary Share Option (Right to Buy) $5.73 2026-10-31 8,726 8,726 Direct
Ordinary Shares Ordinary Share Option (Right to Buy) $5.21 2027-10-31 9,597 9,597 Direct
Ordinary Shares Restricted Stock Units $0.00 2,879 2,879 Direct
Ordinary Shares Restricted Stock Units $0.00 18,721 18,721 Direct
Ordinary Shares Ordinary Share Option (Right to Buy) $6.41 2028-10-31 6,240 6,240 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2025-10-31 7,505 7,505 Direct
2024-04-29 5,000 5,000 Direct
2022-08-30 20,014 20,014 Direct
2024-10-31 5,025 5,025 Direct
2026-10-31 8,726 8,726 Direct
2027-10-31 9,597 9,597 Direct
2,879 2,879 Direct
18,721 18,721 Direct
2028-10-31 6,240 6,240 Direct
Footnotes
  1. Restricted Stock Units convert into ordinary shares on a one-for-one basis.
  2. All 7,505 options have vested and remain exercisable.
  3. All 5,000 options have vested and remain exercisable.
  4. The exercise price will be paid in pounds sterling, at GBP0.91 per share.
  5. All 5,025 options have vested and remain exercisable.
  6. 5,818 options have vested on October 31, 2018 and remain exercisable, 2,908 options will vest on October 31, 2019.
  7. 3,199 options vested on October 31, 2018 and remain exercisable, 3,199 options will vest on October 31, 2019 and 3,199 options will vest on October 31, 2020.
  8. On October 31, 2017, the Reporting Person was granted 5,758 restricted stock units, of which 2,879 have vested and have been exercised. The remaining 2,879 restricted stock units will vest on October 31, 2019.
  9. On October 31, 2018, the Reporting Person was granted 18,721 restricted stock units, vesting in four equal installments on January 31, 2019, April 30, 2019, July 30, 2019 and October 31, 2019.
  10. The options vest and become exercisable in three equal annual installments beginning October 31, 2019.
  11. Relates to an inadvertent sale of ordinary shares, by the reporting person's broker to settle annual brokerage fees, without the reporting person's prior knowledge or direction.
  12. The reporting person's inadvertent sale of 22 ordinary shares on March 24, 2016 at a price of $8.59 per share reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the reporting person's purchase of 5,000 ordinary shares upon exercise of warrants on October 2, 2015 at a price of $8.80 per share. The reporting person realized no profit in connection with this short-swing transaction.